PDF DatasheetHuman Anti-TOX3 / TNRC9 Antibody Product Attributes
TOX3 / TNRC9 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-TOX3 antibody staining is expected to be primarily localized to the nucleoplasm.
Observed Antibody Staining Data By Tissue Type:
Variations in TOX3 / TNRC9 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in Purkinje cells in the cerebellum. More moderate antibody staining intensity was present in Purkinje cells in the cerebellum. Low, but measureable presence of TOX3 / TNRC9 could be seen inglandular cells in the appendix, glial cells in the caudate nucleus, cells in the molecular layer in cerebellum, glial cells in the cerebral cortex, glandular cells in the colon, peripheral nerve/ganglion in colon, glial cells in the hippocampus, cells in the tubules in kidney, glandular cells in the prostate, rectum and stomach and Leydig cells in the testis. We were unable to detect TOX3 / TNRC9 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of TOX3 / TNRC9 expression as measured by anti-TOX3 / TNRC9 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| TOX3 Variability | + | ++ | ++ | ++ | + | + | ++ | + | + | + | + | + | ++ | + | + | ++ | + | + | + | ++ |
| TOX3 / TNRC9 General Information | |
|---|---|
| Alternate Names | |
| TOX high mobility group box family member 3, TOX3 | |
| Molecular Weight | |
| 63kDa | |
| Chromosomal Location | |
| 16q12.1 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | TOX3 |
| Entrez Gene ID | 27324 |
| Ensemble Gene ID | ENSG00000103460 |
| RefSeq Protein Accession(s) | XP_005255949, XP_016878631, XP_011521304, NP_001139660, NP_001073899 |
| RefSeq mRNA Accession(s) | NM_001080430, XM_005255892, XM_017023142, NM_001146188 |
| RefSeq Genomic Accession(s) | NG_012623, NC_000016, NC_018927 |
| UniProt ID(s) | O15405 |
| UniGene ID(s) | O15405 |
| HGNC ID(s) | 11972 |
| Cosmic ID(s) | TOX3 |
| KEGG Gene ID(s) | hsa:27324 |
| PharmGKB ID(s) | PA162406752 |
| General Description of TOX3 / TNRC9. | |
| It recognizes a 63kDa protein, which is identified as TOX3. It contains a high mobility group (HMG)-box, which regulates Ca2+-dependent transcription in neurons through interaction with the cAMP-response-element-binding protein (CREB). TOX3 appears to be associated with breast cancer susceptibility, is expressed downstream of a cytoprotective cascade together with CITED1, a transcriptional regulator that does not bind directly to DNA. TOX3 is predominantly expressed in the brain, forms homodimers. TOX3 overexpression protects neuronal cells from cell death caused by endoplasmic reticulum stress or BAX overexpression through the induction of anti-apoptotic transcripts, repression of pro-apoptotic transcripts. | |
There are no reviews yet.